Evidence map›Paper›PMID 30790004›Full record

ReviewDer Urologe. Ausg. A2019

[Novel minimally invasive treatment options for male lower urinary tract symptom].

G Magistro, C G Stief, C Gratzke

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

G MagistroUrologische Klinik und Poliklinik der Universität München, Ludwig-Maximilians-Universität München, Marchioninistraße 15, 81377, München, Deutschland. Giuseppe.Magistro@med.uni-muenchen.de.
C G StiefUrologische Klinik und Poliklinik der Universität München, Ludwig-Maximilians-Universität München, Marchioninistraße 15, 81377, München, Deutschland.
C GratzkeKlinik für Urologie, Universitätsklinikum Freiburg, Freiburg, Deutschland.
Ludwig-Maximilians-Universität München · DEUniversity Medical Center Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel minimally invasive treatment options strive for innovative approaches that are equally efficient to standard procedures with a superior safety profile. A true minimally invasive technique can be performed in an ambulatory setting under local anaesthesia and no need for postinterventional catheterization so that quick and problem-free return to everyday life is possible. Sexual dysfunction is a great concern of sexually active patients facing surgery. The novel techniques clearly demonstrate that relief of bothersome lower urinary tract symptoms (LUTS) is possible without compromising erectile and ejaculatory function. Urolift® is an attractive treatment option for carefully selected patients without a middle lobe who have special interest in the rapid and smooth return to daily activity and the complete preservation of sexual function. Rezũm® and AquaBeam® are promising novel techniques that can be also performed in the presence of certain prostatic features like a middle lobe. iTIND® is still in its infancy of clinical evaluation and therefore, its true value still needs to be determined. According to current data the role of intraprostatic injectables for the treatment of male LUTS is still unclear.

Indexed as

Lower Urinary Tract SymptomsProstatic HyperplasiaTransurethral Resection of ProstateHumansMaleMinimally Invasive Surgical ProceduresTreatment OutcomeFexapotide triflutateIntraprostatic injectionLower urinary tract symptomsPRX302Transurethral resection of the prostate

Identifiers

PMID30790004
OpenAlexW3011519137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.